Brief: ViewRay Launches Phase Iii Pancreatic Cancer Study To Demonstrate Superior Overall Survival For Patients Receiving Mri-Guided Ablative Radiation Therapy
18/10/2022 11:51
Oct 18 (Reuters) - ViewRay Inc VRAY.O :
* VIEWRAY LAUNCHES PHASE III PANCREATIC CANCER STUDY TO
DEMONSTRATE SUPERIOR OVERALL SURVIVAL FOR PATIENTS RECEIVING
MRI-GUIDED ABLATIVE RADIATION THERAPY
* VIEWRAY INC - ANTICIPATED ENROLLMENT TARGET IS 267
PATIENTS
(NCT05585554).
Source text for Eikon: ID:nPn8QJjQTa
Further company coverage: VRAY.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Viewray
See all newsBrief: ViewRay Announces Commencement Of Nasdaq Delisting Proceedings Common Stock Expected To Begin Trading On The OTC Markets
Press Digest: Wall Street Journal - July 18
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
ViewRay hits record low on filing for voluntary Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global